抑制性治疗的每月达尔巴万辛剂量:药理动力学估计分析和病例系列
Wesley D Kufel1,2, Kristen Tudahl3, Paul Hutson3
1State University of New York Binghamton School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.
Antimicrobial agents and chemotherapy
|December 19, 2025
概括
每月1,500毫克的达尔巴万辛 (DAL) 显示出抑制保留硬件感染的希望. 这种剂量得到了药理动力学模拟和病例系列的支持,这表明初始加载剂量是不必要的.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 医疗器械 医疗器械
背景情况:
- 保留的硬件和假体感染往往需要长期的抗微生物抑制治疗.
- 目前的治疗选择面临由于抗菌素耐药性,患者过敏症和频繁剂量要求的限制.
- 达尔巴万辛 (DAL) 是一种脂糖类抗生素,在抑制格拉姆阳性感染时可能不常用.
研究的目的:
- 评估达尔巴万辛 (DAL) 在持续硬件感染的抑制疗法中最佳的剂量方案.
- 通过使用in silico模拟来评估每月DAL剂量的药理动力学/药理动力学 (PK/PD) 概况.
- 分析接受DAL治疗硬件相关感染的患者的临床结果.
主要方法:
- 为了预测达尔巴万辛的血清度,进行了in silico药理动力学/药理动力学模拟.
- 评估的主要PK标是足够抑制的自由AUC24/MIC比率大于27.1.
- 对9名每月接受达尔巴万辛 (1,500毫克) 治疗持续硬件感染的患者进行了回顾性审查.
主要成果:
- 药理学模拟表明,每月服用1500毫克的达尔巴万辛可以达到足够的血清度.
- 在模拟中,初始的每周加载剂量没有显著影响药物总暴露.
- 该病例系列在接受每月1,500毫克达尔巴万辛治疗的患者中没有显示抑制性治疗失败,平均为591天.
结论:
- 每月1,500毫克的达尔巴万辛剂量是一种可行的策略,可以抑制阳性保留硬件感染,并得到PK数据和临床结果的支持.
- 对于抑制性治疗来说,每周初始的达尔巴万辛加重剂似乎是不必要的.
- 较低的每月剂量为1000毫克的达尔巴万辛可能适合选择患者,这需要进一步的临床研究.
相关概念视频
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
215
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
215
01:20Estimation of k and VD of Aminoglycosides
193
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
193
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
192
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
192
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
198
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
198
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
194
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
194